読み込み中
Incannex Healthcare Limited is an Australian company dedicated to the research, development, and commercialization of medicinal cannabinoid products. The firm offers pharmaceutical-grade cannabinoid compounds under its proprietary Incannex brand. Its product pipeline includes several key assets: IHL-42X: This compound is currently undergoing Phase II clinical evaluation for the treatment of obstructive sleep apnea (OSA). Incannex partners with The Alfred Hospital and Novotech on this specific clinical program. IHL-216A: Designed to address traumatic brain injury (TBI). Furthermore, the Monash Trauma Group, part of Monash University's Department of Neuroscience, is conducting a study on IHL-216A's protective effects against sports-related concussions. IHL-675A: A unique formulation combining hydroxychloroquine and cannabidiol, developed for both the prevention and management of a range of inflammatory conditions. These include acute respiratory distress syndrome (ARDS), chronic obstructive pulmonary disease (COPD), asthma, bronchitis, rheumatoid arthritis, and inflammatory bowel diseases. Originally established in 2001 as Impression Healthcare Limited, the company officially changed its name to Incannex Healthcare Limited in June 2020. Incannex maintains its corporate headquarters in Sydney, Australia.
前日終値
$3.10
−$0.10 · -3.13%
日中の時刻はETです。市場データは遅延する場合があります。
Incannex Healthcare Limited is an Australian company dedicated to the research, development, and commercialization of medicinal cannabinoid products. The firm offers pharmaceutical-grade cannabinoid compounds under its proprietary Incannex brand. Its product pipeline includes several key assets: IHL-42X: This compound is currently undergoing Phase II clinical evaluation for the treatment of obstructive sleep apnea (OSA). Incannex partners with The Alfred Hospital and Novotech on this specific clinical program. IHL-216A: Designed to address traumatic brain injury (TBI). Furthermore, the Monash Trauma Group, part of Monash University's Department of Neuroscience, is conducting a study on IHL-216A's protective effects against sports-related concussions. IHL-675A: A unique formulation combining hydroxychloroquine and cannabidiol, developed for both the prevention and management of a range of inflammatory conditions. These include acute respiratory distress syndrome (ARDS), chronic obstructive pulmonary disease (COPD), asthma, bronchitis, rheumatoid arthritis, and inflammatory bowel diseases. Originally established in 2001 as Impression Healthcare Limited, the company officially changed its name to Incannex Healthcare Limited in June 2020. Incannex maintains its corporate headquarters in Sydney, Australia.
日中レンジ
現在 $3.10
52週レンジ
現在 $3.10
日中の時刻はETです。市場データは遅延する場合があります。
GoAI スコア
売り
バリュエーション
65
割安
センチメント
59
まちまち
リスク
85
極めて高いリスク
モメンタム
21
弱含み
GoAIの詳細リサーチ
詳しい根拠、カタリスト、リスクを確認できます。
Incannex Healthcare Limited is an Australian company dedicated to the research, development, and commercialization of medicinal cannabinoid products. The firm offers pharmaceutical-grade cannabinoid compounds under its proprietary Incannex brand. Its product pipeline includes several key assets: IHL-42X: This compound is currently undergoing Phase II clinical evaluation for the treatment of obstructive sleep apnea (OSA). Incannex partners with The Alfred Hospital and Novotech on this specific clinical program. IHL-216A: Designed to address traumatic brain injury (TBI). Furthermore, the Monash Trauma Group, part of Monash University's Department of Neuroscience, is conducting a study on IHL-216A's protective effects against sports-related concussions. IHL-675A: A unique formulation combining hydroxychloroquine and cannabidiol, developed for both the prevention and management of a range of inflammatory conditions. These include acute respiratory distress syndrome (ARDS), chronic obstructive pulmonary disease (COPD), asthma, bronchitis, rheumatoid arthritis, and inflammatory bowel diseases. Originally established in 2001 as Impression Healthcare Limited, the company officially changed its name to Incannex Healthcare Limited in June 2020. Incannex maintains its corporate headquarters in Sydney, Australia.
日中レンジ
現在 $3.10
52週レンジ
現在 $3.10
利用可能な期間全体で報告されたマージン。
売上高
営業利益
純利益
| 指標（USD） | 2026年度 | 2025年度 | 2024年度 | 2023年度 | 2022年度 |
|---|---|---|---|---|---|
| 売上高 | — | 8.6万 USD | 1.2万 USD | — | 78.52万 USD |
| 売上原価 | 24万 USD | 24.6万 USD | 10.3万 USD | — | 6335 USD |
| 粗利益 | −24万 USD | −16万 USD | 1.2万 USD | — | 77.88万 USD |
| 研究開発 | 521万 USD | 1074.7万 USD | 1928.12万 USD | 949.57万 USD | 537.13万 USD |
| 販売・一般管理 | 1781.7万 USD | 1312.8万 USD | 2555.7万 USD | 1192.65万 USD | 1017.87万 USD |
| 営業費用 | 2278.7万 USD | 2362.9万 USD | 3005.3万 USD | 2052.66万 USD | 1212.67万 USD |
| 受取利息 | 2.1万 USD | 6.2万 USD | 30.84万 USD | 36.27万 USD | 6269 USD |
| 支払利息 | — | 30.3万 USD | — | — | — |
| 減価償却費と償却費 | 24万 USD | 24.6万 USD | 10.3万 USD | 13.24万 USD | 1135.07万 USD |
| 営業利益 | −2302.7万 USD | −2378.9万 USD | −3004.1万 USD | −2052.66万 USD | −1135.07万 USD |
| 純利益 | −1930.2万 USD | −4688.5万 USD | −1845.9万 USD | −7346.58万 USD | −1490.23万 USD |
会社概要が更新されました 2026年10月11日.
直近の発表実績
直近の発表実績
| 種別 | 発効日 | 詳細 | 基準日 | 支払日 |
|---|---|---|---|---|
株式分割 | 2026年2月27日 | 1:30 | — | — |
株式分割 | 2023年11月30日 | 1:4 | — | — |
発効済み 2026年2月27日
1:30
発効済み 2023年11月30日
1:4
この株式へのエクスポージャーを報告している上場投資信託です。
AIが生成した遅延市場データを、情報提供および教育目的で掲載しています。投資助言ではありません。
